002693.SZ
双成药业
SZSE · Healthcare · C 制造业 · CN
CNY 8.90
−5.42%Year over year
Reported trailing growth
- Revenue
- +71.6%
- EBITDA
- —
- EBIT
- +120.7%
- EPS
- +143.2%
- Free cash flow
- +163.0%
- Operating cash flow
- +490.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- +8.9%
- EBIT
- +108.3%
- Net income
- +28.3%
- EPS
- +35.7%
- Free cash flow
- +126.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026